Cardiovascular diseases are the leading cause of mortality worldwide, especially in developed countries. Global Industry Analysis predicts the cardiovascular drug market will exceed $111.8 billion worldwide by 2014 and continue growing. While sales of LDL-lowering agents and other related drugs continue to increase, there are no medications on the market that can prevent the development of acute myocardial infarction or chronic heart failure or cope with its consequences.
CardioCell hopes to address this unmet need in three major cardiovascular indications:
- Acute Myocardial Infarction (ongoing, Phase II clinical trial)
- Chronic Heart Failure of non-ischemic nature (on-going in United States)
- Peripheral Artery Disease (planned for Phase II)
CardioCell achieves this his through a unique blend of the company’s own expertise and an exclusive, worldwide license from Stemedica Cell Technologies Inc., which manufactures the stem cells. The CardioCell technology comprises strong intellectual-property assets, including one patent and seven in the application process.